Transporter Cocktail

Phase 2Small molecule

Transporter Cocktail is one of 13 small molecule programs targeting Advanced or Metastatic NSCLC. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Metastatic NSCLCRecruiting

Advanced or Metastatic NSCLCPhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Advanced or Metastatic NSCLC

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

2 2

Trodelvy

Gilead

Phase 2

1 3

Paraplatin

AAvyxa

Phase 2

2 4

Imfinzi

AstraZeneca

Phase 1

2 5

DATROWAY

Daiichi Sankyo

Phase 1

1 6

HS-10504

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

1 7

Furmonertinib

AAllist Pharmaceuticals, Inc.

Phase 2

1 8

MEDI5752

AstraZeneca

Phase 1

1 9

TAS6417

Taiho Oncology, Inc.

Phase 2

1 10

AZD2936

AstraZeneca

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Advanced or Metastatic NSCLC

NCT05967689

Clinical

Trials by Indication[1]

Interaction1 trial

Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects

Completed·MMoleac Pte Ltd.·Phase 1·NCT04233437·27 enrolled

Advanced or Metastatic NSCLC1 trial

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.

Recruiting· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 2·NCT05967689·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Transporter Cocktail. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Transporter Cocktail compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Transporter Cocktail. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taiho Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Taiho Oncology, Inc.

Transporter Cocktail

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Interaction1 trial

Advanced or Metastatic NSCLC1 trial

References

Drug Info

Quick Facts

Related News